Laboratory News and Research

RSS

Bruker launches BioPharmaCompass 1.1 software

At the 2012 CASSS 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry, Bruker today launches the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.

From Bruker BioSpin - NMR, EPR and Imaging 12 Sep 2012

Novel method could help advance fight against persistent 'HIV latency'

Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection-by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

Two National University of Singapore scientists win Lasker Awards for medical research

Two scientists from the National University of Singapore (NUS) - Professor Michael Sheetz, Director of the Mechanobiology Institute of Singapore; and Professor Roy Calne, Visiting Professor with the NUS Yong Loo Lin School of Medicine's Department of Surgery - have been conferred the prestigious Lasker Awards for making great advances in medical research.

11 Sep 2012

Stanford and MBL scientists win prestigious Lasker Awards

Scientists who invented new ways to study how "cargo" is moved within cells and, as a result, discovered a new biological motor protein, kinesin, at the Marine Biological Laboratory (MBL) in Woods Hole, Mass., have received the prestigious 2012 Lasker Award for Basic Medical Research, the Albert and Mary Lasker Foundation announced today.

11 Sep 2012

New method can measure methyl mercury at unprecedentedly small concentrations

A strip of glass covered in hairy nanoparticles can cheaply and conveniently measure mercury, which attacks the nervous system, and other toxic metals in fluids.

11 Sep 2012

U of I microbial engineer synthesizes 2-fucosyllactose to protect babies from pathogens

A University of Illinois microbial engineer has synthesized a sugar in human milk that is thought to protect babies from pathogens. That's important because 2FL, the shorthand scientists use to describe this human milk oligosaccharide (HMO), has not been added to infant formula because HMOs are incredibly expensive.

11 Sep 2012

Cardiac stem cells from newborns show stronger regenerative ability

Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells.

11 Sep 2012

RNA researcher to receive 2012 Pearl Meister Greengard Prize from The Rockefeller University

Joan A. Steitz, Ph.D., a pioneer in the field of RNA biology whose discoveries involved patients with a variety of autoimmune diseases, will be awarded the 2012 Pearl Meister Greengard Prize from The Rockefeller University. The prize, which honors female scientists who have made extraordinary contributions to biomedical science and carries an honorarium of $100,000, will be presented at a ceremony on Thursday, November 29 at Rockefeller University's Caspary Auditorium.

11 Sep 2012

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.

11 Sep 2012

Researchers discover small DNA sequence that drives GATA2 protein

The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.

11 Sep 2012

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Annovation Biopharma to develop novel anesthetics with $8M Series A financing

Annovation Biopharma, a biotechnology company focused on creating more effective, safer therapies for anesthesia and critical care, has raised $8M in a Series A financing led by Atlas Venture, Partners Innovation Fund, and new strategic investor The Medicines Company.

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012